CRISPR-Cas guides the future of genetic engineering

By G. Knott, Jennifer A. Doudna. Science, 2018

1,220 citations recorded by the source corpus.

The diversity, modularity, and efficacy of CRISPR-Cas systems are driving a biotechnological revolution. RNA-guided Cas enzymes have been adopted as tools to manipulate the genomes of cultured cells, animals, and plants, accelerating the pace of fundamental research and enabling clinical and agricultural breakthroughs. We describe the basic mechanisms that set the CRISPR-Cas toolkit apart from other programmable gene-editing technologies, highlighting the diverse and naturally evolved systems now functionalized as biotechnologies. We discuss the rapidly evolving landscape of CRISPR-Cas applications, from gene editing to transcriptional regulation, imaging, and diagnostics. Continuing functional dissection and an expanding landscape of applications position CRISPR-Cas tools at the cutting edge of nucleic acid manipulation that is rewriting biology.

Subfields: Molecular Biology

View Paper: https://www.semanticscholar.org/paper/84fe612a0a6cc704924ecafe45b1149ef7b961d8

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

Citations in the corpus

CRISPR technology: A decade of genome editing is only the beginning (2023, background): “Furthermore, this line of research showedhowCRISPR’s RNA-programmed cutting action (5, 6) could be used to alter DNA sequences in any cell with unprecedented ease [reviewed in (7)].”
Genome-wide Programmable Transcriptional Memory by CRISPR-based Epigenome Editing (2021, background): “In particular, clustered regularly interspaced short palindromic repeats (CRISPR)-CRISPR-associated protein 9 (Cas9) and other CRISPR systems can be programmed with a single guide RNA (sgRNA) to introduce DNA breaks at a specified site to inactivate gene function or to stimulate precise DNA editing ”
Delivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery. (2019, positive): “123 – 125 Recently, novel nuclease Cas13a has been shown to preferentially bind and cleave RNA rather than DNA substrates, further expanding the CRISPR toolbox.”